Discovery on Target features diverse and compelling COVID-19 research updates across 6 conference programs Tuesday-Thursday.

Can’t decide on a single program? Just “track hop” at the event – in-person, remotely, or via on-demand access – to maximize your learning across multiple or parallel presentations, in real time or after the conference.

PART A: SEPTEMBER 28 - 29, 2021 EDT

RNA as a Drug Target

View Full Program

TARGETING VIRAL RNAs

Investigating Structural and Epitranscriptomic Landscape of Viral RNAs as a Groundwork for the Identification of RNA Therapeutics
Joanna Sztuba Solinska, PhD, Assistant Professor, Department of Biological Sciences, Auburn University

Modulating the Conformation and Function of Viral RNA with Small Molecules
Amanda Hargrove, PhD, Assistant Professor, Department of Chemistry, Duke University

NMR-Based Fragment Screening of the Conserved Elements of SARS-CoV-2: Lessons Learnt
Harald Schwalbe, PhD, Professor, Department of Organic Chemistry, Johann Wolfgang Goethe University



PROTACs and Targeted Protein Degradation – Part 1

View Full Program

FEATURED PRESENTATION: Targeting RNA-Binding Proteins with RNA PROTACs
Jonathan Hall, PhD, Professor, Department of Chemistry and Applied Biosciences, Institute for Pharmaceutical Sciences, ETH Zurich



Antibodies Against Membrane Protein Targets – Part 1

View Full Program

Challenges and Design Considerations for Coronavirus Antigens
Xiaofeng Xin, PhD, Principal Research Scientist I, AbbVie



3D Cellular Models

View Full Program

Human Lung-on-a-Chip for Modeling Respiratory Viral Infection and Therapeutic Discovery
Haiqing Bai, PhD, Postdoctoral Fellow, Wyss Institute

Engineering High-Content Human-Based Models for Fighting against Diseases and Pandemics
Y. Shrike Zhang, PhD, Assistant Professor, Department of Medicine, Harvard Medical School

Modeling NASH with Patient Liver Derived Organoids
Tobias D. Raabe, PhD, Research Assistant Professor, Perelman School of Medicine, University of Pennsylvania



Immunology and Oncology: Emerging Drug Targets

View Full Program

TOWARDS ORAL-BASED COVID ANTIVIRALS

FEATURED PRESENTATION: Discovery of PF-07321332: An Oral Inhibitor of the SARS-CoV-2 Main Protease for the Treatment of COVID-19
Matthew R. Reese, Principal Scientist, Medicinal Chemistry, Pfizer Global R&D Groton Labs

Update on the ‘Moon Shot’ Consortium to Develop a Novel Antiviral Drug Against SARS-CoV-2
Annette von Delft, PhD, Translational Scientist, Oxford University

PART B: SEPTEMBER 29 - 30, 2021 EDT

Antibodies Against Membrane Protein Targets – Part 2

View Full Program

TARGETING VIRAL SPIKE PROTEINS

Clinical Update for Avdoralimab, an Anti-C5aR Antibody, in Patients with COVID-19 Severe Pneumonia
Éric Vivier, DVM, PhD, CSO, Innate Pharma

Potent Neutralization of SARS-CoV-2 by Human VH Domains
Dimiter Dimitrov, PhD, Professor and Director, Center for Antibody Therapeutics, University of Pittsburgh; Executive Vice President and CSO, Abound Bio

Engineering Specific, High-Affinity Decoy Receptors as Antivirals
Erik Procko, PhD, Assistant Professor, Biochemistry, University of Illinois, Urbana-Champaign

Engineering Broad and Potent Neutralizing Antibodies to Combat SARS-like Viruses
Laura M. Walker, PhD, Director, Antibody Sciences, Adimab LLC